Optimal Albuterol Regimens for Acute Asthma Exacerbations: DBRCT Pilot Study

• Status: Completed
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Our overall objective is to model a pediatric Acute Asthma Clinical Decision Rule (ADR) for personalized medicine by identification of treatment-response phenotypes that are important determinants of outcome. The Specific Aim of this study is to determine the feasibility of this approach by enrolling a pilot cohort of 16 participants in this DBRCT of 4 different albuterol treatment regimens, 2 of which will use 10mg/hr and 2 of which will use 25mg/hr. Within these dosages there will be a pulsed-treatment regimen and a continuous regimen.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vanderbilt University; Vanderbilt University Medical Center
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Albuterol

Criteria

Inclusion Criteria:

• Doctor diagnosed asthma

• Acute asthma exacerbation

• Treatment with systemic corticosteroids and nebulized albuterol

• Ages 5 to 17 years

Exclusion Criteria:

• Other acute or chronic lung disease